How tumors become angiogenic
Trial evidence: Tesamorelin 2mg SC daily sustained GH/IGF-1 elevation, 15-18% visceral fat reduction over 6 months (Falutz, NEJM 2007, PMID 17699044) Ipamorelin 200-300 mcg peak GH 5-10x baseline within 30 minutes, no cortisol/prolactin bump (Raun, EJE 1998, PMID 9539826) GHRH + GHRP synergy 2-3x greater amplitude than either alone (Bowers, JCEM 1991, PMID 2004615) Community protocols extend this evidence base with cycling patterns that weren't studied in the original trials the 5-on/2-off rhythm and 8-week cycles are empirical community consensus, not clinically validated
Hormonal and blood-sugar disruption, including elevated cortisol and prolactin, reduced insulin sensitivity, and hypoglycemia risk tied to IGF-1 receptor activity
The Organon Access Program may be able to answer questions about benefits investigations, billing and coding, co-pay assistance for eligible patients, and prior authorizations and appeals
Studies show that doses of 1000-2000 mcg can help treat deficiency, even if injections arent possible
